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Abstract
Background: Human Disabled-2 (DAB2), is a multi-function signalling molecule that it is frequently down-regulated in 
human cancers. We aimed to investigate the possible tumour suppressor effect of DAB2 in nasopharyngeal carcinoma 
(NPC).
Methods: We studied the expression of DAB2 in NPC cell lines, xenografts and primary tumour samples. The status of 
promoter methylation was assessed by methylation specific PCR and bisulfite sequencing. The functional role of DAB2 
in NPC was investigated by re-introducing DAB2 expression into NPC cell line C666-1.
Results: Decrease or absent of DAB2 transcript was observed in NPC cell lines and xenografts. Loss of DAB2 protein 
expression was seen in 72% (33/46) of primary NPC as demonstrated by immunohistochemistry. Aberrant DAB2 
promoter methylation was detected in 65.2% (30/46) of primary NPC samples by methylation specific PCR. Treatment 
of the DAB2 negative NPC cell line C666-1 with 5-aza-2'-deoxycytidine resulted in restoration of DAB2 expression in a 
dose-dependent manner. Overexpression of DAB2 in NPC cell line C666-1 resulted in reduced growth rate and 35% 
reduction in anchorage-dependent colony formation, and inhibition of serum-induced c-Fos expression compared to 
vector-transfected controls. Over expression of DAB2 resulted in alterations of multiple pathways as demonstrated by 
expression profiling and functional network analysis, which confirmed the role of DAB2 as an adaptor molecule 
involved in multiple receptor-mediated signalling pathways.
Conclusions: We report the frequent down regulation of DAB2 in NPC and the promoter hypermethylation 
contributes to the loss of expression of DAB2. This is the first study demonstrating frequent DAB2 promoter 
hypermethylation in human cancer. Our functional studies support the putative tumour suppressor effect of DAB2 in 
NPC cells.
Background
Nasopharyngeal carcinoma (NPC) poses one of the seri-
ous health problems in Southern China, including Hong
Kong. It is the fifth commonest cause of cancer deaths in
our male population and affects a younger age population
(< 45 years old) than most of other cancers. The annual
incidence rate in Hong Kong is 29.8/100,000 (Hong Kong
Cancer Registry 2007; http://www3.ha.org.hk/cancereg/
e_stat.asp), in great contrast to those among Caucasians
in other countries (< 1/100,000) [1]. The reason of the
peculiar geographic distribution remains unclear. The
environmental factors and the strong association with
Epstein-Barr virus (EBV) have been implicated [1].
Understanding of the molecular basis of this cancer is
essential to derive effective markers for early diagnosis
and targeted therapies.
Human disabled-2 (DAB2) encodes a 96 kDa mitogen
responsive phosphoprotein that is one of the two mam-
malian orthologues of the drosophila disabled protein. It
contains a proline-rich, SH3-binding domain (PRD) in its
C-terminus, and a phosphotyrosine-binding (PTB)/-
interacting domain (PID) in its N-terminus. The C-termi-
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Page 2 of 12nal PRD interacts with Grb2 by interrupting the binding
of Grb2 and SOS, potentially suppressing the mitogenic
signalling via Ras pathway [2,3]. It also binds clathrin, the
clathrin-adaptor protein AP2 and myosin VI, facilitating
clathrin-coated pit assembly and receptor-mediated
endocytosis [4,5]. The endocytic and vesicular trafficking
function of DAB2 are postulated to mediate its effects on
cellular signalling. The conserved N-terminal PTB of
DAB2 binds to members of the low-density lipoprotein
receptor family [5] and transforming growth factor-β
(TGF-β) type I and II receptors [6], as well as with the Ras
GAP DIP1/2 [7]. The association of DAB2 with multiple
signalling proteins and the lack of intrinsic catalytic
enzyme activity suggest that it is an adaptor molecule
involved in multiple receptor-mediated signalling path-
ways that plays a pivotal role in the cellular homeostasis.
DAB2 is a putative tumour suppressor and plays an
important regulatory role in cellular differentiation.
Induction of differentiation in the absence of DAB2
expression commits the cell to apoptosis [8]. Recently it is
reported that DAB2 functions as a negative regulator of
canonical Wnt signalling by stabilized beta-catenin deg-
radation complex [9]. Decreased expression of DAB2 has
been demonstrated in several cancers including ovarian,
breast, prostate, oesophagus, urinary bladder, colon and
choriocarcinoma [10-17]. Ectopic expression of DAB2
reduced in vitro tumour growth in ovarian, prostatic and
choriocarcinoma cell lines [13,18,19] and significantly
reduced the ability to form tumours in nude mice when
stably expressed in ovarian cancer cells [10]. The involve-
ment of DAB2 in nasopharyngeal carcinoma (NPC) has
not been addressed before. We found that DAB2 tran-
script was absent or significantly down-regulated in NPC
xenografts and cell lines comparing to immortalized nor-
mal nasopharyngeal epithelial cell lines. The protein
expression in primary NPC was also significantly
reduced. The differential expression patterns pointed to a
possible tumour suppressor role of DAB2 in NPC. In the
current study, we aimed to investigate the functional role
of DAB2 in NPC carcinogenesis, and to delineate the
mechanisms leading to the down-regulation of DAB2.
Methods
Cell lines, xenografts, and primary NPC tissues
NPC cell lines (C666-1, HK1 and HONE1), xenografts
(X2117, X666, C15, C17, X1915) were maintained as
described previously [20]. An SV40 large T oncogene
immortalized normal nasopharyngeal epithelial cell line
NP69 was also included in this study [21]. The NPC cell
line C666-1 and all the NPC xenografts harbour EBV,
whereas HK1, HONE1 and NP69 cells are EBV-negative.
Forty-six formalin-fixed paraffin-embedded primary
NPC biopsy samples were retrieved from tissue bank of
the Department of Anatomical and Cellular Pathology at
Prince of Wales Hospital, Hong Kong. All specimens
were taken before treatment and were histologically eval-
uated to be EBV-positive undifferentiated carcinomas as
demonstrated by EBER in situ hybridization. The male to
female ratio of the patients was 3.1:1. The age of the
patients ranged from 16 to 84 years with the median age
of 48. Based on UICC staging classification, 5 patients
had Stage I disease (11%), 14 patients had Stage II (30%),
10 patients had Stage III (22%), 17 patients had Stage IV
disease (37%). The median follow-up time was 57.8
months (range 13.8-95.5 months). The study protocol
was approved by the Joint CUHK-NTE Clinical Research
Ethics Committee, Hong Kong.
5-Aza-2'-deoxycytidine (5-aza) and Trichostatin A (TSA) 
treatment
NPC cell line C666-1 was treated with 1, 5, 10, 15 μM of
5-Aza-2'-deoxycytidine (Sigma, St. Louis, MO) for 3 days.
Culture medium with fresh 5-aza was replenished every
24 hours. For TSA treatment, cells were incubated with
50, 100 and 200 ng/ml TSA (Sigma) for 24 hours. Syner-
gistic effect of 5-aza and TSA was tested by treating cells
with 5 μM of 5-aza for 3 days followed by 100 ng/ml of
TSA for 24 hours.
Immunohistochemistry
Immunohistochemistry was performed on the Ventana
Nex ES automated stainer (Ventana Corporation, Tucson,
AZ) using anti-DAB2 antibody (1:50, Santa Cruz Biotech-
nology, Santa Cruz, CA). The cytoplasmic expression of
DAB2 was assessed by assigning a proportion score and
an intensity score. The proportion score was according to
proportion of tumour cells with positive cytoplasmic
staining (0, none; 1, < = 10%; 2, 10 to < = 25%; 3, > 25 to
50%; 4, > 50%). The intensity score was assigned for the
average intensity of positive tumour cells (0, none; 1,
weak; 2, intermediate; 3, strong). The cytoplasmic score
of DAB2 was the product of proportion and intensity
scores, ranging from 0 to 12. The cytoplasmic expression
was categorized into low (score 0 to 3), intermediate
(score 4-6), and high (score 7-12). The scoring was inde-
pendently assessed by two pathologists (K.F.T. and
A.W.C.)
Bisulfite sequencing and methylation specific PCR (MSP)
Bisulfite sequencing and MSP has been described previ-
ously [22,23]. A total of 47 CpG sites spanning approxi-
mately 800-bp on the 5'CpG island of DAB2 gene were
analyzed by bisulfite sequencing (Additional file 1 Figure
S1). This region covered the critical transcriptional regu-
latory domains sufficient for DAB2 expression in epithe-
lial cells [24,25]. The PCR Primers are listed in Table 1.
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Full length DAB2 was amplified from TrueORF cDNA
clone (Origene, Rockville, MD) and inserted into
pcDNA3.1(+) (Invitrogen) to produce DAB2 expression
vector. pcDNA3.1(+)/DAB2 were transfected into C666-1
cells using FuGENE HD (Roche, Mannheim, Germany).
Restoration of DAB2 expression was confirmed by west-
ern blot analysis using DAB2 antibody (1:4000, Santa
Cruz Biotechnology, Santa Cruz, CA, USA).
Flow cytometric analysis
Cells transfected with pcDNA3.1(+) or pcDNA3.1(+)/
DAB2 were subjected to flow cytometric analysis as
described previously [22].
Cell proliferation and monolayer colony formation assay
Cell proliferation of DAB2 transfected C666-1 cells was
assessed using CellTiter 96® Non-Radioactive Cell Prolif-
eration Assay (MTT) (Promega, Madison, WI) according
to the manufacturer's instructions. For monolayer colony
formation assay, C666-1 cells were culture overnight in 60
mm plates and transfected with pcDNA3.1(+)/DAB2 or
empty vector. Forty-eight hours later the transfectants
were re-plated in triplicate and cultured for 21 days in
selection medium containing G418 (500 μg/ml). Surviv-
ing colonies were stained with Gentian violet after meth-
anol fixation and counted. The experiments were
repeated in triplicate.
Microarray analysis
Gene expression analysis of C666-1 transiently trans-
fected with pcDNA3.1(+)/DAB2 for 24 hours as com-
pared with cells transfected with empty vectors as
controls were subjected to microarray analysis using 4 ×
44 K Whole Human Genome Oligo Microarray system
(Agilent Technologies, Santa Clara, CA). The experiment
was done in duplicate. Microarray slides were scanned
using Agilent G2505C microarray scanner (Agilent). The
images were quantified with Feature Extraction Software
(Agilent Technologies). The raw data were quantile nor-
malized by robust multiarray average (RMA) algorithm
and analyzed in Partek Genomics Suite 6.4 (Partek, St.
Charles, MO). Differential gene expression was evaluated
using one-way ANOVA. A fold-change cut-off of 1.5 and
p < 0.01 was set to identify differentially expressed genes.
The Ingenuity Pathways Analysis (IPA, Ingenuity® Sys-
tems, http://www.ingenuity.com) was utilized to identify
network of interacting genes and the biological functions
that were most significant to the data set. Fisher's exact
test was used to calculate a p-value determining the prob-
ability that each biological function assigned to that data
set is due to chance alone. A p-value of less than 0.01 was
considered significant.
Quantitative real-time PCR (QRT-PCR)
QRT-PCR was performed using premixed primers and
probes from TaqMan® Gene Expression Assays (Applied-
biosystems, Foster city, CA) and run on ABI 7500 real
time fast PCR system (Appliedbiosystems). All reactions
were done in triplicate. The relative expression level was
normalized with beta-actin and calculated using the 2^(-
Delta Delta Ct) method [26].
Table 1: PCR primers used for bisulfite sequencing and methylation specific PCR
Primer sequence Product size
Bisulfite sequencing
Region1 Forward 5'-TAGTTTTTTGTTTAAAGGGTTTTAACGGGT-3' 365 bp
Region1 Reverse 5'- ACCTAAACTTAATAACTCCCCCTCA -3'
Region2 Forward 5'- ATTTTGGTATATTTTTGGGGAGTTT-3' 360 bp
Region2 Reverse 5'- CCCAAACACAAAATCTCATTTCTA -3'
Methylation specific PCR
Methylated Forward 5'-ATTTTTCGTCGGGAGTGGTC-3' 79 bp
Methylated Reverse 5'-GCAACGAATACGACGAACCT-3'
Unmethylated Forward 5'-GGGAGTGGTTGTGTGGTTTT-3' 103 bp
Unmethylated Reverse 5'-AACTTGGGGACACCCAAA-3'
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MAP kinase pathways were studied by western blotting
according to standard procedures as described previously
[22,23]. Anti-ERK1/2, anti-phospho-ERK1/2 and anti-c-
Fos antibodies came from Cell Signalling Technology,
Inc. (Beverly, MA). Anti-GAPDH (Calbiochem, La Jolla,
CA) was used as a loading control.
Statistical Analysis
Mann-Whitney U test was used to compare the data and
p value < 0.05 was considered as statistically significant.
Statistical analyses were performed using SPSS 16.0 soft-
ware (SPSS Inc., Chicago, IL, USA).
Results
Loss of DAB2 expression in NPC
We used QRT-PCR assay to assess the DAB2 mRNA
expression level in NPC cell lines, xenografts and immor-
talized normal nasopharyngeal epithelial cell line. As
shown in Figure 1, DAB2 expression was undetectable in
NPC cell line C666-1 and all 5 NPC xenografts (X2117,
X666, C15, C17 and X1915). In NPC cell lines HK1 and
HONE1, the DAB2 expression levels were significantly
reduced comparing with the expression level of immor-
talized normal nasopharyngeal epithelial cell line.
Immunohistochemistry was performed in 46 NPC
biopsy samples to determine the DAB2 protein expres-
sion in primary NPC. We first optimized the staining
condition using human ovarian tissue. Intense DAB2
immunoreactivity was observed in the ovarian surface
epithelial cells (Figure 2A). In normal nasopharyngeal
epithelium, intermediate to high level of cytoplasmic
stain was observed as demonstrated in Figure 2B. In NPC
biopsy samples, thirty-three cases (72%, 33 out of 46)
were negative for DAB2 stain. Focal immunoreactivity
was observed in the remaining 13 NPC biopsies and all
Figure 1 DAB2 mRNA expression in NPC cell lines, xenografts and normal nasopharyngeal epithelial cell line. The QRT PCR was done in trip-
licate. The error bars represent the standard deviations. P value (* p < 0.05, **p < 0.001) refers to the comparison with normal nasopharyngeal epithelial 
cell line NP69.
Figure 2 Immunohistochemical analysis of DAB2 expression in 
NPC. (A) Surface epithelium of ovary served as positive control (original 
magnification × 400). (B) Normal nasopharyngeal epithelium (× 400). 
Arrows indicate the positive epithelium. (C) Cytoplasmic staining in a 
NPC biopsy (× 200). Arrows indicate positive NPC cells. (D) Negative 
staining in NPC cells. The dendritic cells (arrows) in the stroma served 
as internal positive controls (× 200).
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of positive and negative DAB2 immunoreactivity in NPC
biopsies were shown in Figurea 2C and 2D, respectively.
The dendritic cells distributed in the stroma showed
strong immunoreactivity for DAB2. It has been reported
that macrophage and fibroblast-like cells in the stroma
expressed DAB2 [12,27]. Therefore, they served as inter-
nal positive controls for the staining as shown in Figure
2D. DAB2 immunoreactivity was not associated with age,
gender, stage of disease, disease specific survival or over-
all survival of the patients.
Promoter methylation contributes to DAB2 down 
regulation in NPC
Sheng et al. characterized human DAB2 gene and identi-
fied a CpG island (39 CpG sites) spanning 420-bp
sequence 5' of exon 1. They found that this 420-bp puta-
tive promoter contains the transcription start site and is
sufficient for active transcription in epithelial cells [24].
Since the expression of DAB2 was down-regulated in
NPC, we examined whether the gene was silenced by pro-
moter hypermethylation. Bisulfite sequencing was per-
formed to determine the methylation pattern of the
5'CpG island of DAB2 in NPC cell lines and xenografts.
Two regions were amplified for analysis: region 1 with 24
CpG sites and region 2 with 23 CpG sites (Figure 3A and
Additional file 1 Figure S1). As shown in Figure 3B, dense
methylation in both region 1 and region 2 was observed
in NPC cell line C666-1, NPC xenografts X2117 and
X666, in which no DAB2 mRNA expression was detected.
In NPC cell lines HK1 and HONE1, and immortalized
normal nasopharyngeal epithelial cell line NP69, where
the DAB2 expression was retained, the promoter region
was unmethylated. These results indicated that aberrant
methylation contributed to the loss of DAB2 expression
in NPC cell lines and xenografts.
We further analyzed the DAB2 promoter methylation
status in primary NPC tissues by MSP. Aberrant methyla-
tion on the promoter region of DAB2 was detected in
65.2% (30/46) of NPC primary tumour biopsy samples.
Representative results were shown in Figure 3C. Our data
suggested that aberrant promoter methylation is a com-
mon event that contributes to the down regulation of
DAB2 expression in NPC. However, no correlation could
be demonstrated between DAB2 hypermethylation and
clinicopathologic features including age, gender, stage of
disease, disease specific survival or overall survival of the
patients.
We treated NPC cell line C666-1, which shown com-
plete loss of DAB2 expression, with demethylation agent
5-aza-2'-deoxycytidine. DAB2 mRNA expression was
restored in a dose dependent manner as demonstrated by
quantitative real time PCR (Figure 4A). Using bisulfite
sequencing, partial demethylation of DAB2 promoter was
detected in C666-1 cells after 5-aza treatment (Figure
4B). The promoter region we analyzed included the
major GATA6 cis elements that are critical for the tran-
scriptional regulatory of DAB2 gene [25]. The finding
further confirmed that DAB2 down regulation was medi-
ated by promoter methylation. Induction of DAB2 tran-
scription by histone deacetylase inhibitor has been
reported previously [19]. In C666-1 cells, histone
deacetylases inhibitor (HDACi) trichostatin A (TSA)
could also restore the DAB2 mRNA expression (Figure
4A). However, we didn't observe a synergistic induction
of DAB2 transcript after combined treatment with 5-aza
and TSA in comparison to TSA treatment alone (Figure
4A).
DAB2 re-expression reduced in vitro growth of C666-1 cells
To evaluate the potential tumour suppressor effect of
DAB2 in NPC, we transfected full length DAB2 cDNA in
pcDNA3.1(+) expression vector into C666-1 cells. The
expression of transfected cDNA was confirmed by west-
ern blot analysis. The endogenous DAB2 expression was
completely loss in wild type C666-1 cells. Re-expression
of DAB2 could be detected at 12 hours after transfection
and remained at high level after 72 hours (Figure 5A).
MTT assay was done to assess the proliferation rate of the
transfectants (Figure 5B). DAB2 suppressed the prolifera-
tion of C666-1 cells in comparison to vector controls and
mock transfection controls (transfection reagent only).
We further evaluated the growth inhibitory effect of
DAB2 in NPC cells using anchorage-dependent colony
formation assay. C666-1 cells transfected with
pcDNA3.1(+)/DAB2 or empty vector were selected with
G418 for 21 days. Exogenous DAB2 resulted in 35%
reduction in colony formation compared to vector-trans-
fected control (Figure 5C). Since a growth inhibitory
effect was observed in DAB2 transfected NPC cells, we
analyzed the transfectants for cell cycle parameters using
flow cytometry. Twenty-four hours after transfected with
pcDNA3.1(+)/DAB2, empty vector, or mock transfection,
the C666-1 cells were harvested and analyzed. Under our
experimental condition, DAB2 did not cause significant
change in cell cycle parameters, although a slightly reduc-
tion (3.9%) of S phase cells was observed in DAB2
expressing cells (Figure 5D).
DAB2 inhibited serum-induced c-Fos expression
DAB2 was identified as a mitogen responsive phosphop-
rotein and its growth suppression function is thought to
be secondary to the inhibition of MAP kinase pathway
[28]. To explore the mechanism for tumour suppression
by DAB2 in NPC, we studied the effect of DAB2 on
serum-induced MAP kinase signalling in NPC cells
C666-1. We transfected C666-1 cells with empty vector
or DAB2 expression vector. The cells were allowed to
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Figure 3 Promoter methylation of DAB2 in NPC. (A) The CpG island of DAB2. (B) Bisulfite sequencing of DAB2 CpG island. Open circles represent 
unmethylated CpG sites; filled circles represent methylated CpG sites. (C) Representative MSP results in primary NPC samples. M: methylated allele; U: 
unmethylated allele. IVD: In vitro methylated DNA.
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Page 7 of 12recover for 24 hours, followed by starvation in serum-free
medium for another 18 hours, and then stimulated with
20% serum in culture medium. The cells were harvested
at various time points and assayed for MAP kinase path-
way by western blotting. C666-1 cells exhibited no basal
MAP kinase activity after starvation (Figure 6). Activa-
tion of MAP kinase, as demonstrated by phospho-ERK1/
2 immunoblot, was observed at 5 minutes after serum
stimulation and attenuated after 30 minutes. MAP kinase
activation was not affected by DAB2 expression. The p-
Figure 4 Restoration of DAB2 expression by 5-aza and TSA in C666-1 cells. (A) The relative DAB2 mRNA expression was calculated comparing 
each sample to no treatment controls. * p < 0.05. A1 - A15, T50 - T200 and A5+T100 refer to the concentrations of A (5-aza) and T (TSA). The treatment 
protocol has been described in method section. (B) Bisulfite sequencing of DAB2 promoter on C666-1 cells before and after 5-aza treatment.
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tion in transient DAB2-transfected cells compared with
vector-transfected cells. C-Fos was induced at 30 minutes
after serum stimulation and reached the maximal level at
60 minutes. In DAB2 expressing C666-1 cells, a much
weaker c-Fos induction was observed compared with vec-
tor-transfected control cells. C-Fos is an immediate early
gene that is required for malignant tumour growth. DAB2
might exert the tumour suppression function by inhibit-
ing c-Fos expression in NPC.
Identification of cellular networks and pathways regulated 
by DAB2
To search for potential genes and pathways regulated by
DAB2 in NPC, we compared the expression profile of
C666-1 cells overexpressing DAB2 to vector control-
transfected cells. The expression of DAB2 protein after
transfection was confirmed by western blotting. The
expression profile was performed using Agilent 4 × 44K
whole human genome oligonucleotide (60 mer) array.
Differential gene expression was evaluated using one-way
ANOVA. Within the ANOVA model, linear contrasts
were used to compare the transiently transfected cells
carrying DAB2 to the vector control. To adjust for multi-
ple testing errors, a step-up Benjamini false discovery
rates (FDR) adjustment was used. FDR was set to be less
than 20% to produce a list of significantly differentially
expressed genes for each contrast described above.
A total of 628 differentially expressed genes were iden-
tified at expression cutoff of 1.5 fold and p = 0.01. Top 50
significantly up-regulated and down-regulated genes
were listed in Additional file 2 Table S1. Some of the
genes were confirmed by real time QRT-PCR (Additional
file 2 Table S2). Each gene identifier was mapped to its
corresponding gene object in the Ingenuity Pathways
Knowledge Base. Two hundred and nine of these genes,
called focus genes, were overlaid onto a global molecular
Figure 5 Re-expresssion of DAB2 reduced in vitro growth of C666-1 cells. (A) Western blot analysis of DAB2 transfected C666-1 cells. V: vector 
control; D: DAB2 transfectant. (B) Cell proliferation as determined by MTT assay. The mean and SD obtained from five experiments were plotted. ** (p 
< 0.01). (C) Anchorage-dependent colony formation assay. The experiment was done in triplicate and the error bars represent standard deviations. *p 
< 0.05. (D) Cell cycle distribution of C666-1 cells transfected with DAB2, vector control and mock transfected cells by flow cytometry analysis.
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Ingenuity Pathways Knowledge Base. Networks of these
focus genes were then algorithmically generated based on
their connectivity. A total of 32 partially overlapped net-
works were identified. Of which 9 networks involved
more than 1 focus gene. Top functions of these genes
were related to cancer, cell death, endocrine systems dis-
orders, cellular and organismal development, cell-to-cell
signalling and interaction, grow and proliferation, cell
cycle and cell morphology. Additional file 1 Figure S2
shows the most significant three gene networks. The first
Network, which was built from 22 genes and received the
highest IPA score, was centred on MAPK, RAS, AKT and
IGF1 and associated with cancer, cell death and endo-
crine system disorders. The second network, incorporat-
ing 22 genes, was centred on NFκB and AP1, and
associated with endocrine system disorders, metabolic
diseases. The third network built on 23 genes was mostly
centred around ERK and associated with cardiovascular,
cellular and organismal development.
The use of IPA identified the mitotic roles of Polo-like
kinase, Wnt/beta-cantenin signalling and cell cycle regu-
lation by BTG family proteins as the most significant
canonical pathways altered upon DAB2 transfection
(Table 2, Additional file 1 Figure S3). All three canonical
pathways were down-regulated in DAB2-expressing
C666-1 cells.
Discussion
Although decrease or absent of DAB2 has been reported
in several cancer types, the status in NPC has not been
explored. In this study, we screened NPC cell lines and
xenografts for DAB2 expression level and observed a sig-
nificant down-regulation of DAB2 transcript level in
NPC cells comparing to immortalized normal nasopha-
ryngeal epithelial cells. We further examined the DAB2
protein expression level in primary NPC biopsy samples
using immunohistochemistry. DAB2 expression was
retained in normal nasopharyngeal epithelium. However,
complete loss of DAB2 expression was seen in 72% of pri-
mary NPC. The frequent down-regulation of DAB2 in
NPC implied that it might be a tumour suppressor gene
involved in NPC pathogenesis.
Several genetic and epigenetic processes contribute to
the silencing of tumour suppressor genes, including loss
of genetic materials, mutation, promoter methylation,
histone acetylation and post-transcriptional regulation by
micro RNAs, etc. Loss of heterozygosity and deletion of
chromosome 5p13, where DAB2 is located, is uncommon
in NPC according to our previous studies [29-31]. Since
DAB2 down-regulation was observed in transcription
level, post-transcriptional regulation by micro RNAs is
unlikely. In colorectal and gastric cancer cell lines,
GATA4 and GATA5 genes and their target genes includ-
ing DAB2 promoter were found to be hypermethylated,
suggesting epigenetic silencing may be responsible for
loss of DAB2 protein expression in these cell lines [32].
Zhou et al reported that the transcription regulation of
DAB2 is mediated through histone acetylation and by
specific transcription factors such as GATA6 but not by
DNA methylation in urothelial carcinoma [16,19]. They
found a critical regulatory region on DAB2 promoter (-
295 and -120-bp upstream from exon 1) that contains the
major GATA6 cis elements. We sequenced the promoter
Figure 6 Transfection of DAB2 inhibited serum-induced c-Fos expression. Twenty-four hours after transfection with vector or DAB2, C666-1 cells 
were cultured without serum for 18 hours and then stimulated with serum for 0, 5, 15, 30, 60, 90 minutes. Cells were immediately washed with cold 
phosphate-buffered saline and collected by scraping. The cell lysates were analyzed for MAP kinase pathway by western blotting using anti- total and 
phospho-ERK1/2 and c-Fos.
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domains described by Zhou et al and no mutation was
found in NPC cell lines and xenografts [Genbank:
HM135031 to HM135036], suggesting mechanisms other
than mutation on transcription factor binding sites
should contribute to the down-regulation of DAB2.
Previous studies suggested that DNA methylation in
the promoter region of DAB2 is infrequent in esophageal
and breast cancers [11,15]. In contrast to these studies,
we found that promoter methylation of DAB2 is observed
in 65.2% (30/46) of primary NPC. Methylation status on
the promoter region was associated with the expression
level of DAB2 in NPC cell lines and xenografts. Treat-
ment with demethylation agent 5-aza-2'-deoxycytidine
restored the DAB2 expression in NPC cell line in a dose-
dependent manner. The results strongly suggested that
promoter methylation is one of the frequent epigenetic
mechanisms contributed to the inactivation of DAB2 in
NPC.
One of the unique features of NPC in our locality is that
the majority of NPC is undifferentiated carcinoma and
consistently associated with Epstein Barr virus (EBV). In
our previous studies, we have demonstrated the frequent
hypermethylation of multiple genes in NPC including
RASSF1A, RARβ, DAP-kinase, p15, p16, TSLC1, DLEC1,
etc. [33-36]. The alterations are accompanied by methyla-
tion of EBV genome, suggesting a process of virus-associ-
ated hypermethylation in cancer development. EBV-
associated gastric cancer showed global CpG island
methylation on promoter region of various cancer-related
gene and demonstrated methylation phenotype [37]. The
mechanisms by which EBV infection promotes DNA
methylation are largely unknown. Recent studies sug-
gested that EBV latent membrane protein 1 (LMP1) acti-
vates cellular DNA methyltransferases, and therefore
down-regulates the expression of critical host genes using
cellular DNA methylation machinery [38].
The high frequency of epigenetic inactivation of DAB2
in NPC has led to the hypothesis that DAB2 might be a
tumour suppressor gene in this cancer. In keeping with
this hypothesis, we demonstrated that exogenous expres-
sion of DAB2 suppressed NPC tumour growth in vitro as
demonstrated by cell proliferation assay, and reduced the
anchorage-dependent colony formation. Previously,
DAB2 has been found to exert the tumour suppressor
effect by uncoupling MAP kinase activation and c-Fos
expression [28]. In keeping with this finding, our results
showed that serum-induced c-Fos expression was greatly
reduced in DAB2-expressing NPC cells compared to vec-
tor-transfected controls, whereas the activity of MAP
kinase did not changed. DAB2 might restrict the nuclear
entry of MAP kinase by mediating the trafficking of car-
gos containing importins away from nuclear pore, thus
preventing the activation of c-Fos by MAP kinase in
nucleus [39].
To further explore the functional role of DAB2 in NPC
carcinogenesis, we compared the expression profile of
DAB2 expressing-C666-1 cells and the vector control-
transfectants. Functional network analysis of differen-
tially expressed genes revealed that the networks involved
were centred on signalling proteins NFκB, AKT, TGF-
beta, and ERK, which confirmed the role of DAB2 as an
adaptor molecule involved in multiple receptor-mediated
signalling pathways.
Recent studies demonstrated that DAB2 interacts with
Axin and contributes to the maintenance of the differen-
tiated state and restrain Wnt-mediated proliferation [40].
Over expression of DAB2 inhibits Wnt-3A-induced accu-
mulation of beta-catenin, decreased Dishevelled-3 (Dvl-
3)/Axin interactions and maintains Axin/beta-catenin/
GSK3 interactions, and attenuates Wnt/beta-catenin-
mediated signalling. In this study, pathways analysis of
the microarray data confirmed the involvement of DAB2
in Wnt/beta-catenin signalling pathway. Attenuation of
canonical Wnt/beta-catenin signalling was observed in
C666-1 cells expressing DAB2 (Additional file 1 Figure
S2). Although the role of the Wnt pathway in NPC has
not been fully explored, there is abundant evidence that
aberrant Wnt signalling plays a role in NPC development
[41]. Delineation of the regulatory role of DAB2 might
provide insight into the molecular mechanisms of NPC
development.
The mitotic role of Polo-like kinase is the top-scored
canonical pathway identified in DAB2 expressing C666-1
Table 2: Top three canonical pathways in DAB2-expressing C666-1 cells
Name p-value Ratio Molecules
Mitotic roles of Polo-like 
Kinases
1.96E-03 13/62 (0.21) ANAPC2, ANAPC5, ANAPC13 CCNB1, CDC25A, HSP90AB1, PPP2R4, 
PPP2R1B, PPP2R2A, PPP2R2C, PPP2R5E, SMC1A, TGFB1
Wnt/beta-catenin Signalling 8.83E-03 26/165 (0.158) AKT1, APC2, DKK2, DKK3, DVL1, FZD9, FZD10, GNAQ, HDAC1, 
HNF1A, MDM2, PPP2R4, PPP2R1B, PPP2R2A, PPP2R2C, PPP2R5E, 
SOX8, SOX5, TGFB1, UBB, UBD, WIF1, WNT2, WNT16, WNT5B, WNT8B
Cell cycle regulation by BTG 
Family Proteins
1.78E-02 8/36 (0.222) CCNE1, CDK4, E2F6, PPP2R4, PPP2R1B, PPP2R2A, PPP2R2C, PPP2R5E
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Page 11 of 12cells. Polo-like kinases play critical roles during multiple
stages of cell cycle progression, starting from control of
the G2/M transition through phosphorylation of
CDC25C and mitotic cyclins and a role in the DNA dam-
age checkpoint adaptation to prevent entry into mitosis
[42]. DAB2 is phosphorylated by CDC2 during mitosis
phase, which promotes the binding of DAB2 to the pepti-
dylprolyl isomerase Pin1 [43]. The interaction between
DAB2 and Pin1 facilitates DAB2 dephosphorylation.
However, little is known about the role of DAB2 in
mitotic control. The observation that the mitotic role of
Polo-like kinase pathway is down-regulated in DAB2
expressing C666-1 cells is of interest. DAB2 might exert
its growth inhibitory effect through the regulation of
mitosis. The exact role of DAB2 in mitotic control
remains to be elucidated.
Conclusion
DAB2 is a multi-function, multi-potency adaptor protein.
Eliminating DAB2 expression may contribute to disrup-
tion of various signalling pathway in NPC. Further stud-
ies are needed to delineate the mechanisms underlying its
tumour suppressor effect in NPC.
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